CI

At a glance

ClinicalIndex Comparison Record
N/AUnknown· 308 enrolled
Drug / intervention
Ripretinib Oral Tabletdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05697107
NCT05697107N/AUnknown
CompareCT.gov

A Large Scale, Multicenter, Real-World Study on Patients With Advanced GIST Receiving Ripretinib

Peking University·observational·Posted Jan 25, 2023·Updated Jan 25, 2023

In Brief

An observational study evaluating Ripretinib Oral Tablet for Gastrointestinal Stromal Tumors. Targeting 308 participants across 1 site.

Detailed Summary

to evaluate the clinical efficacy, safety and predictive factors of ripetinib in Chinese patients with advanced GIST in the real world

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGastrointestinal Stromal Tumors
CountriesChina
CollaboratorsFirst Affiliated Hospital, Sun Yat-Sen University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Sun Yat-sen University, Fudan University, Xiangya Hospital of Central South University, Fujian Medical University Union Hospital, The First Affiliated Hospital with Nanjing Medical University, First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Chongqing Medical University, RenJi Hospital

Timeline

N/AUnknownOverdue
20222023202420252026
First PostedJan 25, 2023
Enrollment StartMay 20, 2021
Primary CompletionAug 30, 2022
Study CompletionDec 30, 2023
TodayJul 1, 2026
Enrollment to primary: 1.3 yearsPosted 3.4 years ago

Interventions

Ripretinib Oral Tabletdrug

Oral kinase inhibitor